FINWIRES · TerminalLIVE
FINWIRES

Aptorum's Merger Target DiamiR Begins Alzheimer's Biomarker Study With AlzLabs

By

Aptorum Group (APM) said Monday its merger target, DiamiR Biosciences, is collaborating with AlzLabs Precision Diagnostics to evaluate blood-based biomarkers for Alzheimer's disease.

The companies will generate protein and microRNA data from blood plasma samples collected from participants whose amyloid status was confirmed through amyloid PET imaging, according to a statement.

The study will assess biomarker panels both on their own and in combination with DiamiR's CogniMIR technology, the companies said.

Aptorum and DiamiR previously agreed to an all-stock merger under which DiamiR will become a wholly owned subsidiary of Aptorum and the combined company will operate as Niki BioSolutions, with its stock expected to trade under the ticker symbol NIKI.

Shares of Aptorum were up more than 2% in Monday trading.

Price: $0.85, Change: $+0.02, Percent Change: +2.19%

Related Articles

Wire

Pacgold Says Non-Executive Chair Resigns

Pacgold (ASX:PGO) said Caoilin Chestnutt has resigned as its non-executive chair, effective June 19, according to a Monday Australian bourse filing.Richard Hacker was appointed as Chestnutt's successor, per the filing.The company's shares fell 2% in recent trading on Monday.

ASX:PGO
Wire

Update: EQT Holdings Plans to Stop Offering Independent Superannuation Trusteeship, Shift Focus to Core Corporate Trustee Services; Shares Fall 13%

(Updates with the stock movement in the headline and last paragraph.)EQT Holdings (ASX:EQT) plans to stop offering independent superannuation trusteeship as part of a strategic decision to focus on its core corporate trustee services and trustee and wealth services businesses, according to a Monday filing with the Australian bourse.The decision follows a review that evaluated market dynamics, operating requirements, long-term growth opportunities, as well as shifting client needs as two of the company's major superannuation clients are considering a move to internalize trusteeship.If Equity Trustees Superannuation retires from its superannuation trustee appointments, EQT Holdings will be required to repay operational risk financial requirements loan facilities of AU$36 million, the company said.It added that the move is expected to result in a one-off non-cash impairment charge estimated at about AU$13 million in fiscal 2026 results, while total legal and advisory costs related to the review are expected to be about AU$6.3 million for the fiscal year.Additionally, the company also expects to incur about AU$2.2 million of net legal and advisory costs in the second half of the fiscal year for legal proceedings related to the Shield and First Guardian Master Funds.EQT Holdings said its Superannuation Trustee Services business accounted for 5% of the group's net profit before tax in the first half of fiscal 2026.The company's shares fell 13% in recent Monday trade.

ASX:EQT
Wire

NobleOak Life Reports 9% Embedded Value Growth; Achieves Fiscal 2026 In-Force Premium Guidance; Shares Up 3%

NobleOak Life (ASX:NOL) said it increased its embedded value by 9% year over year to AU$2.34 per share, or AU$217.7 million, as of the end of 2025, according to a Monday filing with the Australian bourse.Excluding a previously disclosed one-off Victorian stamp duty provision, annual embedded value growth would have been about 13%, reflecting profitable growth of in-force premiums and continued market share gains, the company said.It also reported AU$538 million of in-force premiums as of May 31, up 16% from a year earlier, marking the achievement of its fiscal 2026 guidance for growth of more than 15%, per the filing.The company's shares gained nearly 3% in recent Monday trade.

ASX:NOL